Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]
Mergers & Acquisitions
Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires
Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on […]
Boyd acquires MBK Tape Solutions, expands expertise in wearables, transdermal patches
Boyd Corporation announced today that it acquired MBK Tape Solutions and its multi-layered adhesive products. MBK manufactures and develops complex multi-layered adhesive products that bond, mount, monitor and protect for stick-to-skin applications in the regulated medical industry. Pleasanton, California-based Boyd said in a news release that the acquisition strengthens its medical material science capability across […]
Inhaled drug delivery tech company Aerami to go public through SPAC merger
Aerami Therapeutics announced today that it entered into a merger agreement with FoxWayne Enterprises Acquisition Corp. (NSDQ:FOXWU). Through the definitive business combination agreement with the special purpose acquisition company (SPAC), Aerami, a developer of inhaled therapies for treating respiratory and chronic diseases, will be listed on the Nasdaq market as “Aerami Therapeutics Holdings, Inc.” According […]
Better Therapeutics closes SPAC merger, debuts on Nasdaq
Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to […]
Report: Medtronic in negotiations to buy Israel-based insulin pump maker Triple Jump
Reports in Israel say that Medtronic (NYSE:MDT) has entered talks to acquire Triple Jump for $300 million. Calcalist reported that the proposed acquisition, which is in advanced negotiations, follows a 2020 investment into Triple Jump made by Medtronic that included an option to purchase the insulin pump maker. Triple Jump — a startup based in […]
Alfred E. Mann Foundation sells insulin infusion pump IP to Medtronic
The Alfred E. Mann Foundation for Scientific Research (AMF) today announced the sale of intellectual property to Medtronic (NYSE:MDT). As part of the transaction of IP related to implanted infusion pumps, AMF will work with Medtronic to develop the technology into a next-generation implantable insulin pump for people living with hard-to-treat type 1 diabetes in […]
Philip Morris’ $1.2B offer for inhaled drug delivery tech developer becomes unconditional
Philip Morris (NYSE:PM) announced today that its offer to buy inhaled drug delivery technology developer Vectura has become unconditional. Having received valid acceptances for or acquired 74.77% of Vectura shares, in excess of the 50% required under the acceptance condition, along with confirming that all other conditions to the offer have been satisfied or waived, […]
Better Therapeutics expects $113M SPAC merger to go through in October
Better Therapeutics announced today that it expects its merger with Mountain Crest Acquisition Corp to close next month. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. At the time of the announcement, the companies expected the merger to be completed some time […]
Sanofi to acquire Kadmon for $1.9B
Sanofi (NYSE:SNY) announced today that it entered into a definitive merger with therapeutic developer Kadmon (NSDQ:KDMN) for $1.9 billion. The acquisition adds Rezurock (belumosudil), a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for patients over 12 years old who have failed at least two prior lines of systemic therapy, to Sanofi’s transplant portfolio. […]